OMEGA Study: A Study of the Safety and Feasibility of Up-titration With INT301 in Adults With Sensitivity to Peanut

Inclusion Criteria: Participant must be 18-55 years of age inclusive, at the time of signing the informed consent. Female participants of childbearing potential or male participants with female partners of child-bearing potential must utilize highly effective birth control method(s) throughout the study and for 30 days after the final dose of study drug. Acceptable methods of contraception include: complete abstinence, male or female condoms with spermicide, oral or implanted contraceptives, or vasectomy. For female participants of child-bearing potential: Negative serum beta human chorionic gonadotrophin (HCG) pregnancy test at screening. Capable of giving signed informed consent as described in Appendix 1 which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. Meets at least one of the following conditions * Positive skin prick test (SPT) (wheal at least 3 mm greater than control) AND/OR Peanut specific IgE \>0.35 kU/L * Convincing clinical history of allergic reaction to peanut within 1 hour of ingestion for at least 3 months prior to screening. * Failed an oral food challenge (OFC) of \< 100mg of peanut protein at screening. * Participant willing and able to undergo the procedures required by the protocol, including, assessment completion, protocol compliance, and participation in the placebo dosing period(s). Exclusion Criteria: * History of severe anaphylaxis to peanut, defined as hypoxia, hypotension, or neurologic compromise (cyanosis or oxygen saturations \< 92% at any stage, hypotension, confusion, collapse, loss of consciousness, or incontinence) * Significant medical condition (e.g., liver, kidney, gastrointestinal, cardiovascular, hematologic, or pulmonary disease) which would make the subject unsuitable for induction of food reactions * Eosinophilic or other inflammatory (e.g. celiac) gastrointestinal disease * Psychiatric disorders that the Investigator believes will interfere with study assessments * Uncontrolled asthma, defined by at least one of the following conditions: * \- FEV1 \<80% of predicted, or ratio of FEV1 to forced vital capacity (FEV1/FVC) \<75% of predicted, with or without controller medications. * \- Inhaled corticosteroids (ICS) dosing of \>500mcg daily fluticasone (or equivalent ICS based on NHLBI dosing chart. * \- One hospitalization in the past year for asthma * \- An ER visit for asthma within six months prior to screening * Planned dental surgery during from screening until study exit * Moderate or advanced periodontal disease. * Current pregnancy or lactating